
    
      Participants will receive either MK-1454 monotherapy or MK-1454 in combination with
      pembrolizumab for up to 35 cycles (approximately 2 years). Participants will undergo at least
      a 24-hour inpatient observation period following the first dose administration of MK-1454 on
      Cycle 1 Day 1 in Part 1. For Part 2, the length of the observation period following
      administration of the first dose of MK-1454 on Cycle 1 Day 1 is at least 8 hours.
    
  